mRNA |
FSC231 |
CTRPv2 |
pan-cancer |
AAC |
-0.023 |
0.7 |
mRNA |
Sunitinib |
GDSC1000 |
pan-cancer |
AAC |
0.017 |
0.7 |
mRNA |
Bortezomib |
GDSC1000 |
pan-cancer |
AAC |
-0.016 |
0.7 |
mRNA |
ATRA |
CTRPv2 |
pan-cancer |
AAC |
0.011 |
0.7 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.012 |
0.7 |
mRNA |
JQ-1 |
CTRPv2 |
pan-cancer |
AAC |
-0.0098 |
0.7 |
mRNA |
lenvatinib |
CTRPv2 |
pan-cancer |
AAC |
-0.011 |
0.7 |
mRNA |
navitoclax:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.011 |
0.7 |
mRNA |
myriocin |
CTRPv2 |
pan-cancer |
AAC |
-0.025 |
0.8 |
mRNA |
BRD-K79669418 |
CTRPv2 |
pan-cancer |
AAC |
0.016 |
0.8 |